Hepatitis C News and Research

Latest Hepatitis C News and Research

Needle-free methods of immunization

Samir Mitragotri, a professor of chemical engineering at the University of California, Santa Barbara, says the myriad shortcomings of injections have led to active research and development of needle-free methods of immunization.

2 Dec 2005

Five dead, 45 infected, with haemorrhagic fever in Pakistan

According to health officials in Pakistan, haemorrhagic fever has killed at least five people, including a woman doctor, and infected around 45 people the country's biggest city of Karachi.

28 Nov 2005

Largest hepatitis-C U.S. study defines optimal therapy

Final results of the WIN-R trial,[1] the largest hepatitis C study conducted in U.S. patients, showed that weight-based REBETOL (ribavirin, USP) in combination therapy with PEG-INTRON (peginterferon alfa-2b) achieved significantly higher rates of sustained virologic response (SVR)[2] and lower rates of relapse compared to the combination therapy using a flat dose of ribavirin.

14 Nov 2005

New Flu Chip can determine the genetic make-up of types of flu virus in 11 hours

A novel "Flu Chip" developed at the University of Colorado at Boulder that can determine the genetic signatures of specific influenza strains from patient samples within hours may help world health officials combat coming epidemics and pandemics.

7 Nov 2005

HIV-positive patients have shorter survival periods while awaiting liver transplants

A new study on HIV-positive patients eligible for liver transplants found that their survival while waiting for a transplant is significantly shorter than patients who are HIV-negative.

7 Nov 2005

Accumulation of fat in the liver linked to hypertension

The accumulation of fat in the liver, or "fatty liver," resulting from accumulation of central body fat, and perhaps not alcohol consumption, may represent an important underlying mechanism for the association between liver enzymes and hypertension.

3 Nov 2005

Interferon combined with ribavirin treatment is effective for children with chronic Hepatitis C virus

Nearly half of 118 children with chronic Hepatitis C virus (HCV) treated with a combination of interferon-alpha-2b and an optimized dose of ribavirin achieved sustained viral response, and side effects were generally mild.

3 Nov 2005

Breastfeeding does not raise the risk of mother-to-child transmission of hepatitis C virus

One study found that infant girls are twice as likely to be infected as infant boys. Both studies provide new information with which to counsel pregnant women infected with HCV. Taken together, the two new studies expand upon preliminary data from smaller studies of mother-to-child transmission of HCV.

1 Nov 2005

Dead human tissue illegally used in surgery

London Health Sciences Centre is investigating if its surgeons used human tissue products that were recalled because they might have been taken illegally from corpses at funeral homes in the United States.

31 Oct 2005

Morphine withdrawal enhances hepatitis C virus (HCV) replicon expression

Researchers at the University of Pennsylvania have demonstrated that morphine withdrawal complicates hepatitis C by suppressing IFN-alpha-mediated immunity and enhancing virus replication.

30 Oct 2005

Hepatitis C linked to illegal blood donation in China

Research in a rural province of central China has documented that illegal blood donation practices led to high hepatitis C virus (HCV) infection rates in blood and plasma donors during the 1980s and early 1990s, and that failure to screen for HCV in transfusion recipients increased their risk of infection as well

20 Oct 2005

Evidence is mounting to link toxoplasmosis with schizophrenia

Keep pet cats inside, stop feeding strays, cook meat sufficiently and reconsider the way the veterinary profession and public health agencies think - and teach - about the zoonotic pathogen Toxoplasma gondii.

18 Oct 2005

Drug company warns of risk of liver problems with antidepressant

The warning about possible liver-related problems with the depression drug, Cymbalta, has been expanded and doctors are being cautioned against its use in chronic liver disease patients.

18 Oct 2005

Harvard study finds vaccines boost economies of poor countries

Immunization programs in impoverished countries not only save lives, they boost economies, finds a study by researchers with the Harvard School of Public Health (HSPH) published in the current edition of World Economics.

16 Oct 2005

Liver services in the United Kingdom need better funding and better staffing

Mortality from liver disease is increasing in the UK. In 2000 liver disease killed more men than Parkinson's disease and more women than cancer of the cervix. Deaths from alcoholic liver disease has doubled in the past 10 years, while liver disease arising from hepatitis C infection is expected to treble by 2020.

13 Oct 2005

Infants and adolescents vaccinated against hepatitis B are protected for over 10 years after immunisation

...concludes a study in this week’s issue of The Lancet. The authors state that booster doses of vaccine do not seem necessary to ensure long-term protection.

13 Oct 2005

Whooping cough vaccine 90 percent effective

A vaccine to protect adults and adolescents against illness due to Bordetella pertussis infection--or whooping cough--has proved more than 90 percent effective in a national, large-scale clinical study, according to research results published in this week's issue of The New England Journal of Medicine.

12 Oct 2005

New hormone discovery has implications for liver diseases

Researchers at UT Southwestern Medical Center have discovered that the small intestine communicates with the liver to control the production of bile acids - a finding that has great medical implications in treating people at risk for certain types of liver disease.

11 Oct 2005

Third Wave Technologies files patent suits against Chiron and Bayer

The company last Friday filed suit against Digene Corp., seeking a court ruling supporting Third Wave's right to sell its human papilloma virus (HPV) products. Third Wave today also filed suit against Chiron Corp., Bayer Corp., and Bayer HealthCare LLC asking for a similar ruling about its right to sell its hepatitis C virus products.

11 Oct 2005

20 percent of people with chronic hepatitis C who receive a liver transplant will develop advanced cirrhosis

A new study from the University of North Carolina at Chapel Hill School of Medicine may have found a way to identify those at greatest risk, thereby allowing doctors to decide who should receive treatment that could save the transplanted organ. The new findings appear in the October issue of the journal Liver Transplantation.

9 Oct 2005